Didanosine FDA Link Generic

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.

Also Known As:

Videx; 2',3' Dideoxyinosine; NSC-612049; NSC 612049; NSC612049; 2',3'-Dideoxyinosine; Dideoxyinosine; ddI (Antiviral); Inosine, 2',3'-dideoxy-

Pharmalogical Action Categories:

Anti-HIV Agents
Antimetabolites
Reverse Transcriptase Inhibitors

Heterocyclic Compounds: 207
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 664
      - Purine Nucleosides: 362
        Inosine: 914
        Didanosine: 634
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6937
  - Purine Nucleosides: 362
    - Inosine: 914
      - Didanosine: 634
  - Ribonucleosides: 49
    - Inosine: 914
      - Didanosine: 634
  - Deoxyribonucleosides: 34
    - Dideoxynucleosides: 27
      - Didanosine: 634

AI454-176 JAGUAR Study Team Selected Research

AI454-176 JAGUAR Study Team Research Topics

Disease

Drug/Important Bio-Agent (IBA)